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ABSTRAK 
Pengenalan: Ketumbuhan tumor sel raksasa peringkat III Campanacci boleh menyebabkan 
komplikasi osteolisis dan osteoklastik (tulang menjadi reput dan hancur) serta mempunyai 
potensi untuk berlaku ketumbuhan semula dan metastasis pulmonari. Kajian telah 
menunjukkan RANKL sangat merangsang osteoklastogenesis melalui faktor nuklear sel T 
yang aktif, sitoplasmik, bergantung kepada 1 kalori (NFATc1) yang mengawal selia beberapa 
gen spesifik osteoklas. Osteoklastogenesis menjadi terbantut dalam penekanan NFATc1 dan 
sel stem embrionik yang mengetuk keluar dalam vitro. Pada masa kini, peraturan NFATc1 
dalam resorpsi osteoklastik di GCTB masih belum dikaji dan dipelajari  terutamanya dalam 
tahap III GCTB. Adalah penting untuk memahami sepenuhnya patogenesis GCTB yang 
berkaitan osteoklas untuk mengenal pasti pendekatan terapeutik baru dengan mensasarkan 
NFATc1 dalam rawatan GCTB. Kami menganalisis ekspresi NFATc1 immuno-histokimia 
daripada 31 kes berturut-turut tahap III tumor sel raksasa tulang untuk menentukan hubung kait 
antara  klinikal dan patologi. 
Metodologi: Ini adalah kajian rentas keratan pemerhatian yang menilai pengwarnaan 
imunohistokimia untuk NFATc1 dalam kesemua 31 kes berturut-turut peringkat III 
Campanacci sel gergasi tumor tulang (GCTB) yang dikendalikan dan dirawat di Hospital 
Universiti Sains Malaysia dari Januari 2004 hingga Disember 2017. Ungkapan NFATc1 telah 
dinilai oleh pewarna immuno-histokimia di semua bahagian tumor arkib dari setiap pesakit. 
Saiz siri 5 micrometer tebal dipotong dan teknik immuno-histokimia telah dijalankan. Ekspresi 
NFATc1 ke atas kawasan sel tumor nuklear diperiksa menggunakan imunohistokimia. 
Imunohistokimia dinilai dalam tiga kawasan mikroskopik secara rawak menggunakan 
mikroskop cahaya standard pada 40 x 100 pembesaran oleh pemerhati bebas dua buta. Positif 
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untuk ekspresi NFATc1 dinilai mengikut peratusan 1000 sel latar belakang menggunakan 
perisian analisis imej (Olympus - U-RFL-T Cell F). Skor tertinggi dari tiga bidang terpilih 
diambil untuk analisis statistik menggunakan SPSS versi 25.0. Analisis statistik ditentukan 
dengan menggunakan ujian t bebas untuk kumpulan yang berbeza dan dianggap signifikan 
secara statistik apabila nilai p kurang dari 0.05. 
Keputusan: Nilai minimum ekspresi NFATc1 yang didapati sebagai peratusan 1000 sel latar 
adalah 0.81 dengan sisihan piawai 1.48. Julat ini adalah antara 0.0 hingga 6.33 dengan median 
sebanyak 0.07. Perbandingan ekspresi NFATc1 menunjukkan peratusan yang lebih tinggi 
dalam kumpulan pengulangan dengan min 1.01 (SD 0.68) berbanding dengan kumpulan tidak 
berulang dengan min 0.79 (SD 1.55). Perbezaan min ialah 0.22 (-1.06, 1.51). Perbezaan ini 
secara statistik tidak signifikan dengan p> 0.005. Perbandingan ekspresi NFATc1 
menunjukkan nilai min yang lebih tinggi dalam kumpulan metastasis paru-paru iaitu 2.01 (SD 
2.49) berbanding dengan 0.58 (SD 1.13) dalam kumpulan metastasis bukan paru-paru. 
Perbezaan min antara kedua-dua kumpulan adalah 1.43 (-1.63, 4.49) yang secara statistik tidak 
signifikan dengan nilai p> 0.005. 
Kesimpulan:  Kajian ini menunjukkan tidak semua 31 kes GCTB tahap III yang agresif positif 
diwarnai dengan antibodi NFATc1 dengan kemungkinan osteoklas bukanlah faktor utama yang 
bertanggungjawab dalam pemusnahan tulang di dalam kes GCTB. Nilai min ekspresi NFATc1 
didapati secara statistik tidak signifikan apabila diuji terhadap risiko metastasis pulmonari dan 
penyakit berulang, menjadikannya penanda yang tidak berguna untuk meramalkan risiko 
ketumbuhan semula dan metastasis pulmonari dalam tumor sel tumor gergasi yang agresif. 
Kajian ini menunjukkan bahawa terdapat kemungkinan laluan lain yang terlibat dalam 
kemusnahan tulang di dalm kes GCTB yang memerlukan penyelidikan lanjut. 
 
 7 
ABSTRACT 
Introduction: Osteoclastic bone resorption and osteolysis with tendency for local recurrence 
and pulmonary metastases are a common complication of stage III Campanacci giant cell 
tumour of the bone (GCTB). Studies have shown RANKL highly stimulates osteoclastogenesis 
through nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 1 (NFATc1),  
which regulates a number of osteoclast-specific genes. Osteoclastogenesis is retarded in 
NFATc1 suppression and knock-out embryonic stem cells in vitro. To our knowledge, the 
regulation of NFATc1 in osteoclastic resorption in GCTB has not been studied in stage III 
GCTB. It is important to fully understand the osteoclast-associated GCTB pathogenesis to 
identify a new therapeutic approach by targeting NFATc1 in GCTB treatment.  We analyzed 
NFATc1 expression immuno-histochemistry of 31 consecutive cases of stage III giant cell 
tumour of the bone to determine the clinico-pathological correlation. 
Methodology: This observational cross-sectional study evaluated the immunohistochemical 
staining for NFATc1 expression in 31 consecutive cases of stage III Campanacci giant cell 
tumour of bone (GCTB) operated and treated at Hospital Universiti Sains Malaysia from 
January 2004 to December 2017. Expression of NFATc1 was assessed by immuno-
histochemical staining in all representative archive tumour sections from each patient. Serial 
sections of 5 m was cut and underwent immuno-histochemical staining. NFATc1 expression 
over nuclear area of tumor cells was examined using immunohistochemistry. Immunostainings 
were evaluated in three randomly chosen microscopic fields using a standard light microscope 
at 40 x 100 magnification by two-blinded independent observers. Positivity for NFATc1 
expression was assessed according to percentage of 1000 background cells using an image 
analysis software (Olympus – U-RFL-T Cell F). The average score from three selected field 
was taken for statistical analysis using SPSS version 25.0. Statistical analysis was determined 
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using independent t-test for different group and considered statistically significant when p 
values were less than 0.05. 
Results: The mean value of NFATc1 expression obtained as a percentage of 1000 background 
cells was 0.81 with standard deviation of 1.48. The range was between 0.0 to 6.33 with a 
median of 0.07. Comparison of NFATc1 expression showed higher percentage in recurrence 
group with mean of 1.01 (SD 0.68) compared to non-recurrence group with the mean of 0.79 
(SD 1.55). The mean difference was 0.22 (-1.06, 1.51). This difference was statistically not 
significant with p > 0.005. A comparison of NFATc1 expression showed higher mean value in 
lung metastases group which was 2.01 (SD 2.49) compared to 0.58 (SD 1.13) in non-lung 
metastases group. The mean difference between the two groups were 1.43 (-1.63, 4.49) which 
is statistically not significant with the p value > 0.005. 
Conclusions: This study shows not all 31 cases with aggressive GCTB stage III were positively 
stained with NFATc1 antibody showing the possibility osteoclast may have not been the main 
cells responsible in the bone destruction in GCTB condition. The mean value of NFATc1 
expression was found to be statistically not significant when tested against the risk of 
pulmonary metastases and recurrence disease, making it not a useful marker to predict the risk 
of recurrence and pulmonary metastases in aggressive type of GCTB. This study suggested that 
there must be further research to be carried out to understand other different pathways of bone 
resorption and osteolysis in GCTB. 
 
 
 
Keyword; NFATc1, Giant Cell Tumour Bone, Osteolysis 
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1.1 INTRODUCTION 
 
Giant cell tumor of bone (GCT) is a locally, aggressive, benign bone tumor with high 
incidence of recurrence rate and potential of pulmonary metastases [1]. They are one of 
the most common neoplasms, accounting for 5% to 10% of all the primary bone tumours. 
Additionally, they are one of the few osseous bone lesions with female predominance, with 
a female-to-male ratio of 1.3-1.5 to 1. [2] The tumour was thought to be malignant initially 
and was often treated with amputation until it was coined the phrase “giant cell tumour of 
bone,” by Bloodgood in 1912, that the non-malignant behaviour of this lesion was first 
established. [3] 
 
Aggressive lesions are common in Asian population compared to western population and 
they have been shown to have higher rate of recurrence and pulmonary metastases [4, 5]. 
The reason behind this prevalence disparity remains unclear. Studied done by Turcotte et 
al [6] and Arnold et al [7] showing high prevalence and aggressive presentations in 
Southern India and China, where it represents 20% of all biopsied primary tumors of bone. 
In Malaysia, Faisham et al [5] and Ismail et al [8] have reported that most of cases 
presented were staged III GCT which were locally aggressive tumours and have high rate 
of metastasis to lung which range from 19.4% to 30%. The disease typically affects 
skeletally mature adults aged 20 to 40 years of age instead of skeletally immature patients 
which are accounts for fewer than 5% of GCTS of bone and patients aged more than 65 
years which are accounts for less than 10% [9]. Most of the tumours occur around the knee 
joint (50%) followed by distal radius and proximal humerus. [10, 11]. A small percentage 
of tumors occur in the axial skeleton, especially in the spine and sacrum region.  
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GCTs of bone usually presented as solitary lesions except in fewer than 1% of of tumors 
are multicentric. [12] Multicentric GCT of bone tend to be presented in younger patients 
and the tumors often involve the small bones of the hands and feet with more likely to be 
confined to the metaphysis and diaphysis when a long bone is involved.  
 
Radiographic appearance of GCT bone shows an osteolytic lesion with well-defined 
border, eccentrically around the epiphyseal-metaphyseal region which is closed to juxta-
articular location, no mineralized tumour matrix and occurs in patients with closed physes 
[6, 7, 13]. However, GCT of bone may be centered in the metaphysis and may abut the 
physis in children and adolescent with open physes. MRI is crucial for the detection of 
extraosseous soft tissue extension, intra-articular and marrow involvement which is 
important as part of local staging of the disease. Campannaci et al. have classified GCT 
into 3 stages. Stage 3 lesions are aggressive in nature. They are rapidly growing 
symptomatic lesions and are always associated with spontaneous fracture [4]. The tumour 
has fussy borders, with rapid permeative growth and often bulges into the soft tissue. On 
MRI, Stage 3 lesions characterized by breakage of bone cortex and local soft tissue 
extension whereby in MRA (Magnetic Resonance Angiography) showed local increase in 
vascularity. According to Rock et al [14], there is an increased risk of recurrence in stage 
3 tumour. However, many other studies do not regard these staging systems as the 
predictive of the prognosis [1, 15, 16] because of no correlation found between 
aggressiveness seeing in radiography and local recurrence of GCT. 
 
Macroscopically, GCTs of bone are characteristically homogeneous, pale brown, firm 
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though friable, and solid with spongy appearance. However, secondary changes GCT 
presents as a hemorrhagic, soft mass eroding bone. Microscopically, GCT of bone is a 
biphasic lesion composed of multinucleated, osteoclast-like giant cells and mononuclear 
stromal cells with a variable and unpredictable potential for growth. The tumor features a 
usually bland stromal cell population made of osteoblast lineage which are considered as 
a neoplastic factor in GCT, and a second population of monocytes and eponymous 
multinucleated giant cells that are capable for bone resorption.  
 
The stromal cells in the GCT of bone are the neoplastic component of the tumour, releasing 
chemokines (macrophage chemoattractant protein-1 and interleukin (IL)-8) and 
proosteoclastogenic cytokines (macrophage colony stimulating factor (M-CSF), IL-1, IL-
6, IL-11 and IL-17) to promote osteoclast formation and differentiation [17] ), which leads 
to osteoclastogenesis and eventually brings on to osteolytic destruction of bone which are 
a common complication of giant cell tumour of the bone (GCTB) [18-20].  
 
Although numerous attempts have been made to predict the behavior of GCT of bone, 
there has been no definitive clinical, biological or histological parameter to predict the 
aggressiveness of the tumour in terms of potential for local recurrence and to determine its 
metastatic potential [5]. 
 
Immunohistochemical studies give additional useful information in predicting the behavior 
of GCT. Researchers found that the increasing rate of proliferating might increase the 
probability of local recurrence. There are various proliferation markers such as p53, Ki- 
67, PCNA, MMP-2 and MMP-9 (Matrix Metalloproteinase), RANKL, VEGF and recently 
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serum Tartrate-Resistant Acid Phosphatase 5b that had been studied with intention to 
correlate with the aggressiveness of GCT [8, 21-23]. 
 
Study of p53 expression of 50 consecutive cases of stage III GCTB in our institution 
showing p53 expression is a good prognostic factor to predict the risk of local recurrence 
and lung metastasis [22].  Studies by others [17, 24, 25] and from our group have shown 
the importance of receptor activator of nuclear factor κB ligand (RANKL) expression to 
directly stimulate osteoclastogenesis resulting in the osteoclast-mediated bone destruction 
in GCTB [26]. Treatment using a natural RANKL antagonist, osteoprotegerin (OPG) [27] 
a monoclonal antibody directed against RANKL, denosumab [28-30] and an anti-
resorptive drug, bisphosphonate [31], have shown reduced osteoclast resorption. These 
support the understanding that targeting osteoclast formation and resorption is likely 
effective to modulate the osteolysis associated with GCTB [32].  
 
Studies also have shown RANKL highly stimulates osteoclastogenesis through nuclear 
factor of activated T-cells, cytoplasmic, calcineurin-dependent 1 (NFATc1) [33, 34] which 
regulates a number of osteoclast-specific genes [35-37]. Osteoclastogenesis is retarded in 
NFATc1 suppression [38] and knock-out embryonic stem cells in vitro [28, 34]. Apart 
from the RANKL/RANK-NFATc1 system, immunoreceptor tyrosine-based activation 
motif (ITAM)-dependent pathway involving osteoclast-associated receptor (OSCAR) has 
been identified as an important co-stimulatory pathway in osteoclasts [39]. OSCAR has a 
specific role in co-stimulating osteoclastogenesis [39-42] and they may be a positive 
feedback loop involved in the interaction between OSCAR and NFATc1 [39, 43].  
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We evaluated 40 archived tissue specimens diagnosed with GCT of bone, for positivity of 
NFATc1 in hope to find its expression. To our knowledge, the regulation of NFATc1 in 
osteoclastic resorption in GCTB has not been studied. It is important to fully understand 
the osteoclast-associated GCTB pathogenesis to offer a novel therapeutic approach in the 
treatment of this locally destructive primary bone tumor. 
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2.1. General Objectives 
1. To assess the expression of NFATc1 in GCTB patients 
2.2. Specific Objectives 
1. To identify the expression of NFATc1 in GCTB patients by immunohistochemistry 
2. To determine the NFATc1 expression in GCTB in newly diagnosed cases, recurrent or 
non-recurrent cases, lung metastastasis or without lung metastasis, and different grades 
of GCTB. 
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3.2 ABSTRACT 
Introduction: Osteoclastic bone resorption and osteolysis with tendency for local recurrence 
and pulmonary metastases are a common complication of stage III Campanacci giant cell 
tumour of the bone (GCTB). Studies have shown receptor activator of nuclear factor κB ligand 
(RANKL) highly stimulates osteoclastogenesis through nuclear factor of activated T-cells, 
cytoplasmic, calcineurin-dependent 1 (NFATc1), which is involved in the regulation of a 
number of osteoclast-specific genes. Osteoclastogenesis is retarded in NFATc1 suppression 
and knocked-out embryonic stem cells in vitro. To our knowledge, the regulation of NFATc1 
in osteoclastic resorption in GCTB has not been studied in stage III GCTB. It is important to 
fully understand the osteoclast-associated GCTB pathogenesis to identify a new therapeutic 
approach by targeting NFATc1 in GCTB treatment.  We analyzed NFATc1 expression by 
immunohistochemistry technique in 31 consecutive cases of stage III giant cell tumour of the 
bone to understand the clinico-pathological correlation. 
Methodology: This observational cross-sectional study evaluated the immunohistochemical 
staining for NFATc1  expression in 31 consecutive cases of stage III Campanacci giant cell 
tumour of bone (GCTB) operated and treated at Hospital Universiti Sains Malaysia from 
January 2004 to December 2017. Expression of NFATc1 was assessed using immuno-
histochemical staining method in all representative archive tumour sections. Serial sections of 
5 m was cut and underwent immuno-histochemical staining. NFATc1 expression over nuclear 
area of tumor cells was examined and evaluated in three random microscopic fields using a 
standard light microscope at 40 x 100 magnification by two-blinded independent observers. 
Positivity for NFATc1 expression was assessed according to percentage of 1000 background 
cells using an image analysis software (Olympus – U-RFL-T Cell F). The average score from 
three selected field was taken for statistical analysis using SPSS version 25.0. Statistical 
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analysis was carried out using independent t-test for different groups and considered 
statistically significant when p values were less than 0.05. 
Results: The mean value of NFATc1 expression obtained as a percentage of 1000 background 
cells was 0.81 with standard deviation of 1.48. The range was between 0.0 to 6.33 with a 
median of 0.07. Comparison of NFATc1 expression showed higher percentage in recurrence 
group with a mean of 1.01 (SD 0.68) compared to non-recurrence group with a mean of 0.79 
(SD 1.55). The mean difference was 0.22 (-1.06, 1.51). This difference was statistically not 
significant with p > 0.005. A comparison of NFATc1 expression showed higher mean value in 
lung metastases group which was 2.01 (SD 2.49) compared to 0.58 (SD 1.13) in non-lung 
metastases group. The mean difference between the two groups were 1.43 (-1.63, 4.49) which 
is statistically not significant with the p value > 0.005. 
Conclusions: This study shows not all 31 cases with aggressive GCTB stage III were positively 
stained with NFATc1 antibody showing the possibility osteoclast may have not been the main 
cells responsible in the bone destruction in GCTB condition. The mean value of NFATc1 
expression was found to be statistically not significant when tested against the risk of 
pulmonary metastases and recurrence disease, as expected due to lack expression in GCTB 
tissue samples making it not be able to predict the risk of tumour recurrence or lung metastases. 
This study suggested that there must be further research to be carried out to understand other 
different pathways of bone resorption and osteolysis in GCTB . 
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3.3 INTRODUCTION 
 
Giant cell tumour of bone (GCTB) is a benign bone tumour but locally aggressive with high 
incidence of recurrence and potential of pulmonary metastases [1]. High prevalence rate was 
observed in Oriental population especially in Southern India and China, where GCTB 
represents 20% of all primary bone tumour [2]. Aggressive lesions are common in Asian 
population compared to western population. In Oriental population, the reported cases of 
GCTB is associated with a higher rate of recurrence and pulmonary metastases [3, 4]. In 
Malaysia, most of the cases reported were locally aggressive, stage III GCTB with a high rate 
of metastasis to lung ranging from 19.4% to 30% [4, 5].  
 Previous studies [6-8] and from our group [9] have shown the importance of receptor 
activator of nuclear factor κB ligand (RANKL) expression to directly stimulate 
osteoclastogenesis resulting in the osteoclast-mediated bone destruction in GCTB [9]. The key 
pathway in RANKL/RANK osteoclastogenesis is NFATc1. 
We evaluated 31 archived tissue specimens diagnosed with stage III Campanacci 
GCTB. To our knowledge, the regulation of NFATc1 in osteoclastic resorption in GCTB has 
not been studied. It is important to fully understand the osteoclast-associated GCTB 
pathogenesis to offer a novel therapeutic approach in the treatment of this locally destructive 
primary bone tumor. This study aims to identify the expression of NFATc1 by 
immunohistochemistry in stage III Campanacci GCTB and its association with recurrent and 
non-recurrent, lung metastasis or without lung metastasis. 
 
 
 
